login
  Password reminder
Vascular News
Contact the editor Visit Vascular News Twitter feed Visit Vascular News Facebook page
 

OSPREY trial completes US patient enrolment


Thursday, 12 Jul 2012 16:12
Misago
Misago

On 11 July, Terumo Interventional Systems announced the completion of US patient enrolment in the OSPREY (Occlusive/stenotic peripheral artery revascularization study) designed to evaluate the safety and effectiveness of the Misago Self-expanding Stent System. 


OSPREY is a single-arm, multicentre, non-randomised, prospective clinical trial for the treatment of atherosclerotic stenoses and occlusions of the superficial femoral artery that included 200 patients in 31 centres in the USA and 100 patients in seven centres in Japan.

A unique feature of this study is that it simultaneously enrolled patients in the USA and Japan as part of the larger Harmonization by Doing (HBD) pilot programme, a cooperative effort led by the FDA, the MHLW/PMDA (Japan’s regulatory body), Terumo Corporation, based in Tokyo, Japan, and Terumo Medical Corporation, based in Somerset, New Jersey, USA. The HBD initiative is intended to shorten the gap between product approvals in these two countries.


“Peripheral vascular disease is a leading cause of disability in the USA, affecting between 8 and 12 million Americans. It is critical that physicians, and their patients, have faster access to the latest technologies in order to maximise treatment options,” said J Fritz Angle, professor of Radiology, University of Virginia, and US principal investigator in the OSPREY trial. “I look forward to analysing and discussing the OSPREY data with all of the trial investigators. The international experience and testing efficiencies obtained from our collective participation in this HBD initiative could have a dramatic effect on the way important medical devices reach the market in the future.”


The MISAGO Self-expanding Stent consists of a nitinol stent pre-mounted on the distal portion of a rapid-exchange delivery catheter system. The stent has three radiopaque markers located on each end of the stent to help ensure accurate placement in the lesion. The stent is currently available for sale in Europe.

The first US patient implant in the OSPREY trial occurred in September 2010. The primary endpoints of the US arm of the OSPREY study are:

  • Primary stent patency rate at one year as confirmed by duplex ultrasound or angiography.
  • Freedom from major adverse events within 30 days of the procedure, which would result in target lesion revascularisation, amputation of the treated limb or death.

“OSPREY is Terumo Medical Corporation’s first US clinical trial for a premarket approval device and we are exceptionally pleased with its progress. Terumo is greatly appreciative of the tremendous support given by our US clinical investigators, which helped us meet the critical enrolment goal in this landmark HBD initiative,” said James Rushworth, president, Terumo Interventional Systems and Onset Medical Corporation. “The OSPREY trial and the MISAGO Stent truly speak to our three strategic pillars of introducing innovative technologies that create clinical, economic, and quality of life benefits.”




Add New Comment

Most popular


Incraft low-profile endograft launched in Europe and Canada
Wednesday, 10 Sep 2014
Cordis announced on 10 September the launch of its Incraft AAA Stent Graft System, an ultra-low profile device for use during endovascular aneurysm repair (EVAR) for patients suffering from ... Incraft low-profile endograft launched in Europe and Canada

First patient enrolled in US study of Novate’s Sentry IVC filter
Monday, 22 Sep 2014
Novate Medical has announced that Souheil Saddekni, professor of Vascular and Interventional Radiology at the University of Alabama, Birmingham, USA, has enrolled the first patient in the SENTRY IDE ... First patient enrolled in US study of Novate’s Sentry IVC filter

First drug-eluting balloon approved in USA
Friday, 10 Oct 2014
The FDA has approved the Lutonix drug-eluting balloon for the management of peripheral artery disease. This is the first time that the agency has approved such a device for this indication in the USA. First drug-eluting balloon approved in USA

Features


Not all drug-eluting balloons are equal
Wednesday, 15 Oct 2014
Thomas Zeller, Bad Krozingen, Germany, analyses the results of two recent randomised controlled trials comparing drug-eluting balloons to angioplasty alone in femoropopliteal lesions. Not all drug-eluting balloons are equal

Renal stenting may benefit patients excluded from randomised trials, says expert consensus
Wednesday, 15 Oct 2014
Sahil A Parikh, Case Western Reserve University School of Medicine, Cleveland, USA, speaks to Vascular News about the Society for Cardiovascular Angiography and Interventions expert consensus on ... Renal stenting may benefit patients excluded from randomised trials, says expert consensus

Profiles


Martin Björck
Wednesday, 01 Oct 2014
Martin Björck, Uppsala University Hospital, Sweden, holds the only professor-chair of vascular ... Martin Björck

Cliff Shearman
Thursday, 03 Jul 2014
A former president of the Vascular Society of Great Britain and Ireland, Cliff Shearman was ... Cliff Shearman

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions